Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 20:16:77-89.
doi: 10.2147/SCCAA.S432179. eCollection 2023.

Efficacy of Adipocyte-Derived Stem Cells-Conditioned Media in Telogen Effluvium

Shadi Zari  1
Affiliations

Efficacy of Adipocyte-Derived Stem Cells-Conditioned Media in Telogen Effluvium

Shadi Zari. Stem Cells Cloning. .

Abstract

Objectives: To assess the effectiveness of adipocyte-derived mesenchymal stem cells-conditioned media (ADSC-CM) formulation in telogen effluvium patients.

Methods: A retrospective cohort study was conducted at a dermatology clinic in Jeddah, Saudi Arabia. The study included 50 consecutive patients aged 20-70 years, who were diagnosed with telogen effluvium. All patients received five monthly sessions of the same commercial ADSC-CM formulation, using a standardized application protocol. Pre- and post-intervention changes in trichometry parameters were analyzed.

Results: There was a significant increase in mean hair density (up to 29.01 hair/cm2; effect size 0.7-1.0), cumulative hair thickness (up to 2.67 units; effect size 0.7-1.4), and the number of follicular hair units (up to 19.96%; effect size 1.0-1.3) in all scalp regions (p < 0.001), associated with a decrease in mean trichometry-derived Sinclair scale by 0.8-1.3 (p < 0.001). Positive outcomes were observed in 70%-92% of the patients depending on the parameter and scalp region. There was no impact of the patient's age on ADSC-CM efficacy.

Conclusion: ADSC-CM was successfully applied as a new treatment option for patients with telogen effluvium. These findings provide another therapeutic and research area for dermatologists to optimize the management of telogen effluvium and reduce its impact on patients.

Keywords: alopecia; hair loss; hair regeneration; stem cells; stem-cell conditioned media.

PubMed Disclaimer

Conflict of interest statement

The author reports no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Change in hair growth indicators, by scalp region, in patients with telogen effluvium after treatment with ADSC-CM. Left panels show the adjusted relative % change of the 5 positive (green bars) and 2 negative (Orange bars) parameters, where the bar height represents the percentage change in the given parameter by reference to the population baseline mean. Right panels (in blue) show the mean derived Sinclair grade in baseline versus after treatment with ADSC-CM. Panels are organized by scalp region, including frontal (upper), temporal (middle), and occipital (lower) region.
Figure 2
Figure 2
Pre- and post ADSC-CM clinical photography of a 39-year-old female patient showing an aesthetic improvement of the midline and bitemporal areas. The figures have been used with written consent of the patient.
Figure 3
Figure 3
Pre- and post ADSC-CM trichometry of a 39-year-old female patient with telogen effluvium.
See this image and copyright information in PMC

References

    1. Kligman AM. Pathologic dynamics of human hair loss. I. Telogen effluvium. Arch Dermatol. 1961;83(2):175–198. doi:10.1001/archderm.1961.01580080005001 - DOI - PubMed
    1. Grover C, Khurana A. Telogen effluvium. Indian J Dermatol Venereol Leprol. 2013;79(5):591–603. doi:10.4103/0378-6323.116731 - DOI - PubMed
    1. Hughes EC, Saleh D. Telogen effluvium. In: Treasure Island (FL); 2022.
    1. Headington JT. Telogen effluvium. New concepts and review. Arch Dermatol. 1993;129(3):356–363. doi:10.1001/archderm.1993.01680240096017 - DOI - PubMed
    1. Asghar F, Shamim N, Farooque U, Sheikh H, Aqeel R. Telogen effluvium: a review of the literature. Cureus. 2020;12(5):e8320. doi:10.7759/cureus.8320 - DOI - PMC - PubMed